>>SOUTH SAN FRANCISCO, Calif., June 20 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) announced today that it received stockholder approval at the June 20 annual meeting of its stockholders for all eight proposals submitted for stockholder vote and identified in Rigel's 2003 proxy statement. Among the proposals receiving approval were Rigel's recently announced financing, a reverse stock split and changes in Rigel's stock option plans.
Rigel had previously announced that it had entered into a definitive agreement on April 29, 2003 to raise $46 million, pending stockholder approval, from leading biotechnology venture capital investors MPM Capital, Frazier Healthcare, Alta Partners and HBM BioVentures. Rigel anticipates that the financing will be completed next week.
"We are exceptionally pleased that our stockholders have overwhelmingly supported this financing and have endorsed our mission," said James M. Gower, Chairman and CEO of Rigel. "We are excited about the opportunities before us. With the completion of this financing now imminent, we are planning to pursue proof of efficacy in humans with three promising drug candidates. Our candidate for allergic rhinitis, R112, is already in phase I/II clinical studies. We intend to file an IND to initiate a phase I clinical trial for a novel potential treatment of hepatitis C late this year and to begin clinical studies with a third product candidate for rheumatoid arthritis in 2004."
Proxy Proposals Approved
At the June 20 annual meeting, Rigel's stockholders approved eight proposals which are as follows with the stockholder vote in favor of each proposal listed as a percentage of the total shares outstanding:
1. The terms of the financing with MPM Capital, Frazier Healthcare, Alta
Partners and HBM BioVentures was approved by approximately 82% of
shares outstanding.
2. The amendment of Rigel's certificate of incorporation to effect a
reverse stock split of Rigel's outstanding common stock of not less
than 1-for-2 and not more than 1-for-20 and the authorization of
Rigel's board of directors to select the final ratio and effect the
split was approved by approximately 82% of outstanding shares.
3. An amendment to Rigel's 2000 Equity Incentive Plan to (a) increase the
aggregate number of shares of common stock authorized for issuance
under such plan, (b) add an evergreen feature that provides for
automatic annual increases in the total number of shares authorized for
issuance under such plan and (c) combine Rigel's 2001 Non-Officer
Equity Incentive Plan with Rigel's 2000 Equity Incentive Plan and
terminate its 2001 Non-Officer Equity Incentive Plan was approved by
approximately 72% of outstanding shares.
4. An amendment to Rigel's 2000 Non-Employee Directors' Stock Option Plan
to (a) increase the aggregate number of shares of common stock
authorized for issuance under such plan and (b) increase the size of
automatic and annual option grants under such plan was approved by
approximately 73% of shares outstanding.
5. An amendment to Rigel's 2000 Employee Stock Purchase Plan to (a)
increase the aggregate number of shares of common stock authorized for
issuance under such plan and (b) amend the evergreen feature of such
plan was approved by approximately 77% of shares outstanding.
6. The repricing, at the discretion of Rigel's board of directors, of
outstanding options to purchase shares of Rigel's common stock issued
under its 2000 Equity Incentive Plan, 2001 Non-Officer Equity Incentive
Plan and 2000 Non-Employee Directors' Stock Option Plan was approved by
approximately 72% of the shares outstanding.
7. The re-election James M. Gower and Donald G. Payan as directors to hold
office until Rigel's 2006 annual meeting of stockholders was approved
by approximately 87% of the shares outstanding.
8. The selection by Rigel's audit committee of Ernst & Young LLP as
independent auditors of Rigel for the fiscal year ending December 31,
2003 was approved by approximately 92% of the shares outstanding.
Final vote counts will be noted in Rigel's Form 10-Q for the quarter ending June 30, 2003.
Rigel's board of directors will determine and announce the specifics of the reverse split in the next several days. Once the reverse split has been effected, Rigel anticipates that the financing will close shortly thereafter. Upon the closing of the financing, two additional members of Rigel's board of directors will be appointed.<<
snip
Cheers, Tuck |
